Boostrix

Boostrix

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Per 0.5 mL dose Diphtheria toxoid not <2 IU, tetanus toxoid not <20 IU, 3 Bordetella pertussis antigens (pertussis toxoid 8 mcg, filamentous haemagglutinin 8 mcg, pertactin 2.5 mcg)
Indications/Uses
Booster vaccination against DPT in individuals ≥4 yr. Passive protection against pertussis in early infancy following maternal immunisation during pregnancy.
Dosage/Direction for Use
Single 0.5 mL dose by deep IM inj.
Contraindications
Hypersensitivity or patients having signs of hypersensitivity after previous administration of DPT vaccines. Encephalopathy of unknown aetiology, occurring w/in 7 days following previous vaccination w/ pertussis-containing vaccine. Transient thrombocytopenia or neurological complications following earlier immunisation against diphtheria &/or tetanus.
Special Precautions
Postpone vaccination in patients suffering from acute severe febrile illness. Not to be administered IV. Patients w/ thrombocytopenia or bleeding disorder. Immunosuppressed patients. History or family history of convulsions & adverse event following DPT vaccination. Syncope. Perform review of medical history & clinical exam before vaccination. Carefully consider giving doses of pertussis-containing vaccines for temp ≥40°C w/in 48 hr of vaccination, not due to another identifiable cause; collapse or shock-like state (hypotonic-hyporesponsiveness episode) w/in 48 hr of vaccination; persistent, inconsolable crying lasting ≥3 hr, occurring w/in 48 hr of vaccination; convulsions w/ or w/o fever, occurring w/in 2-3 days of vaccination. Defer pertussis immunization in childn w/ progressive neurological disorders including infantile spasms, uncontrolled epilepsy or progressive encephalopathy. Lactation.
Adverse Reactions
Irritability; somnolence, headache; inj site reactions (including pain, redness, swelling), fatigue, malaise. Anorexia; diarrhoea, vomiting, GI disorders, nausea; fever ≥37.5°C (including >39°C), inj site reactions (eg, inj site mass & abscess sterile); dizziness.
Drug Interactions
Concomitant use w/ immunosuppressants.
MIMS Class
Vaccines, Antisera & Immunologicals
ATC Classification
J07AJ52 - pertussis, purified antigen, combinations with toxoids ; Belongs to the class of pertussis bacterial vaccines.
Presentation/Packing
Form
Boostrix susp for inj 0.5 mL
Packing/Price
0.5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in